Commerce Bank Takes Position in Stryker Corporation $SYK

Posted by Francis Steltz on Aug 23rd, 2026

Commerce Bank purchased a new position in Stryker Corporation (NYSE:SYK – Free Report) in the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 120,562 shares of the medical technology company’s stock, valued at approximately $37,958,000.

Other hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new position in shares of Stryker in the 2nd quarter worth approximately $205,000. Marshall Wace LLP raised its stake in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after acquiring an additional 77,831 shares in the last quarter. Nebula Research & Development LLC bought a new position in shares of Stryker during the 2nd quarter worth approximately $219,000. Finally, HUB Investment Partners LLC purchased a new stake in Stryker during the second quarter valued at approximately $253,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Performance

Shares of NYSE SYK opened at $329.86 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock has a market cap of $126.52 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 2.10 and a beta of 0.76. The company has a 50 day simple moving average of $326.99 and a two-hundred day simple moving average of $332.64.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analysts Set New Price Targets

SYK has been the topic of several analyst reports. Argus set a $370.00 price target on shares of Stryker in a report on Thursday, July 9th. Robert W. Baird set a $385.00 price objective on Stryker in a report on Friday, May 1st. BMO Capital Markets began coverage on Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. Citizens Jmp dropped their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research note on Monday, August 3rd. Finally, Royal Bank Of Canada reduced their target price on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Read Our Latest Report on Stryker

Insider Activity

In related news, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 665,370 shares of company stock worth $216,238,501 in the last ninety days. Company insiders own 4.60% of the company’s stock.

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.